Concepedia
Statistics
Publications
8
Citations
162
H-Index
Active since
2018
Affiliations
Bristol-Myers Squibb (United States)(Current)
IBM (United States)
The University of Texas at Austin
Rina Mehta is an author at Bristol-Myers Squibb (United States).
Publications per year
2018–2023
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Elyse Swallow, Oscar Patterson‐Lomba, Lei Yin et al. · Journal of Comparative Effectiveness Research · 2020 · 44 citations · Full text
Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Léorah Freeman, Arianna Kee, Marc Tian et al. · Drugs - Real World Outcomes · 2021 · 24 citations · Full text
Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
Robert J. Fox, Rina Mehta, Timothy Pham et al. · BMC Neurology · 2022 · 19 citations · Full text
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
James D. Bowen, Rina Mehta, Corey Pelletier et al. · Advances in Therapy · 2020 · 18 citations · Full text
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
Steven R. Feldman, Corey Pelletier, Kathleen Wilson et al. · Journal of Comparative Effectiveness Research · 2018 · 16 citations
1–5 of 8